GQ Bio Therapeutics

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liege, Belgium

Biotechnology,gene therapy,osteoarthritis,drug development,human medicine,animal health,and musculoskeletal disease

Gq bio therapeutics operates in the Biotechnology industry.

Gq bio therapeutics's revenue is 11m - 100m

Gq bio therapeutics has 11 - 50 employees.